Elevian is developing new medicines that promote recovery and regeneration, specifically targeting the treatment of stroke and aging-related diseases using a recombinant protein called rGDF11.

Elevian

Viewport Meta

SSL by Default

Euro

Google Tag Manager

HSTS

Google Font API

Google Analytics

Content Delivery Network

Global Site Tag

Co-Founder and CEO

Mark Allen

Cofounder and Chairman

Sebastian Giwa

Legal

Tom McCracken

Senior Director of Asset Management

Elena Labini

Director, Laboratory Operations

Ryan Walker

Director, Protein Biochemistry & Neuroscience

Yongting Wang

Scientist I

Catherine Deatherage, PhD

Chief Operating Officer

Jeff Imbaro

Research Associate

Katie LeDonne

Member, Executive Leadership

Manisha Sinha

Dr. Sebastian Eriksson Giwa

Caleb Bell

Brock Reeve

Co-Founder

New England Companies With Fewer Than 1000 Employees (Top 10K)

East Coast Companies With Fewer Than 50 Employees (Top 10K)

Biotechnology Early Stage Companies With Less Than $1B in Revenue

East Coast Early Stage Companies With Less Than $1B in Revenue

Elevian’s founders discovered circulating blood factors that regulate aging, including GDF11, which broadly stimulate regeneration of brain, heart, pancreas, muscle, and other tissues.  Elevian is developing therapeutics that stimulate regenerative capacity, to treat and prevent age-related disease.

Prime Movers Lab

Series A - Elevian

Seed Round - Elevian

Convertible Note - Elevian

Allston

Massachusetts

United States

North America

MatchCraft Utilizes Machine Learning in Automated PPC to Take Your Online Advertising Campaigns to the Next Level

Elevian snags $40M for stroke recovery and age-related diseases

Elevian Announces $15 Million Equity Financing

Anti-aging biotech Elevian raises $15M as it looks to the clinic

Sarcopenia, H1 2020 - Armgo Pharma Inc, Elevian Inc, Immusoft Corp, Neurotune AG & Ridgeline Therapeutics LLC - ResearchAndMarkets.com

The Top 10 Companies Working to Increase Longevity

Can Young Blood Transfusions Cure Age-Related Diseases?

A recombinant protein developed to facilitate recovery of motor function post-stroke by promoting neovascularization, neurogenesis, and reducing inflammation.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Oct 26, 2024 10:21 PM	d41c3a21
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Oct 26, 2024 10:21 PM	1a4fa01e
crunchbase trigger	general	Dec 4, 2024 8:54 AM	4fac7eb6
crunchbase profile	general	Dec 4, 2024 3:50 PM	21378a10
li profile	general
translate crunchbase fundingrounds	general	Dec 4, 2024 4:43 PM	ad977d25
peers	general	Oct 26, 2024 10:21 PM	a60fbe83
news basic	general	Oct 26, 2024 10:21 PM	61d8cf1a
bundesanzeiger	filings
financials download nd	financials
private financials	financials

ELEV

COM:ELEVIAN

Elevian